100 results
Page 2 of 5
8-K
EX-99.1
7aqgbhmhogmv3bqpf
8 Dec 22
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
8:00am
8-K
EX-99.1
mpcd2p4
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-99.1
2aimk0jrtu
8 Sep 22
Regulation FD Disclosure
6:10am
8-K
EX-99.1
4ap2jx5yjjdv69
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
o8i2e1
1 Jun 22
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen
8:00am
8-K
bm6up
1 Jun 22
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen
8:00am
8-K
EX-99.1
962zi30o6cc a969zf
19 May 22
Regulation FD Disclosure
8:00am
8-K
EX-99.1
0izh1
9 May 22
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
ka149 5n1d
2 May 22
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
8:00am
8-K
EX-99.1
ki4pvxb4lrqas
29 Mar 22
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
8:00am
8-K
EX-99.1
yyyqonjfn d9u680
15 Mar 22
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
8:00am
8-K
a9n71w oimgu739v
15 Mar 22
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
8:00am